Key Takeaway: Aquestive Therapeutics has reported its financial results for Q2 2026, highlighting the successful completion of a human factors validation study and a pharmacokinetic study for its Anaphylm sublingual film. The company remains on track to resubmit its New Drug Application (NDA) to the FDA in the third quarter of 2026 and is actively engaging in pre-launch activities.
Market Sentiment Analysis
POSITIVE FACTORS
Successfully completed human factors validation study.
Pharmacokinetic study for Anaphylm sublingual film was completed.
On track to resubmit Anaphylm NDA to the FDA in Q3 2026.
Continues pre-launch medical affairs activities.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
21%
average across 5 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
DESF
Phase 2 · Allergic Reaction
Full Press Release Details
Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026 Continues pre-launch medical affairs activities and payer engagement On track to begin ex-U.S.
Frequently Asked Questions
What studies were completed by Aquestive Therapeutics?
Aquestive Therapeutics completed a human factors validation study and a pharmacokinetic study for Anaphylm.
When will Aquestive resubmit the Anaphylm NDA?
The company plans to resubmit the Anaphylm NDA to the FDA in Q3 2026.
What activities is Aquestive engaged in pre-launch?
Aquestive is continuing its medical affairs activities and payer engagement ahead of the Anaphylm launch.